Alumis’ Post

View organization page for Alumis, graphic

4,461 followers

Today we announced that patient dosing has commenced in the ONWARD Phase 3 clinical program evaluating ESK-001, an oral #TYK2 inhibitor, in moderate-to-severe Plaque #psoriasis. Topline data anticipated in 2026. Learn more: https://bit.ly/4c2rSvs  

  • No alternative text description for this image
Manish Kothari

Founder, Member of Board & Strategic Advisor

1mo

Wishing the entire clinical team all the very best !

Like
Reply
Alex Iakimov, M.D.

VP of Radiology at IAG | Life-sciences | CRO

1mo

Congratulations, Jörn Drappa and the Alumis team! Exciting news on the Phase 3 trial. Best wishes for successful outcomes, new trials, and impactful partnerships! 🌟

Fantastic news Jorn and Alumis team!

Like
Reply
Shawn Friend

Port City Labs I Managing Partner

4w

Great work Jörn!

Like
Reply
Charlene Liao

CEO and Board Chair of Immune-Onc Therapeutics, Inc.

1mo

Congratulations Jörn Drappa

See more comments

To view or add a comment, sign in

Explore topics